口服与鼓室内注射糖皮质激素治疗伴前庭功能障碍的特发性突发性感音神经性聋的前庭预后:随机对照试验方案
特发性突发性感音神经性聋(ISSNHL)伴前庭功能障碍者预后较差,糖皮质激素是常规治疗但前庭预后研究较少。
要点
- 伴前庭功能障碍的ISSNHL患者约28-57%,前庭功能受损被视为预后不良指标。
- 本试验首次以随机对照设计比较口服与鼓室内糖皮质激素对前庭功能恢复的影响。
- 主要结局采用五项前庭功能检查,于基线、4周和8周评估。
核心结论
- 本试验旨在比较口服与鼓室内注射糖皮质激素在伴前庭功能障碍的ISSNHL患者中前庭功能恢复模式与轨迹的效果。
研究设计与样本
- 随机、结局评估者和分析者盲法的对照临床试验。
主要发现
- 背景指出前庭功能障碍发生于约28-57%的ISSNHL病例,被视为临床表现和预后不良指标。
- 既往ISSNHL干预研究仅关注听力结局,对前庭功能障碍预后关注甚少。
关键数值与推荐
- 主要结局为前庭功能结局,采用感觉组织试验、冷热试验、视频头脉冲试验、颈性前庭诱发肌源性电位和眼性前庭诱发肌源性电位评估。
- 次要结局包括自我报告前庭功能障碍症状、头晕相关残障、眩晕与耳鸣视觉模拟量表及纯音测听。
- 主要结局于基线、随机后4周和8周评估;次要结局于基线及随机后1、2、4、8周评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic sudden sensorineural hearing loss (ISSNHL) is a rapid-onset sensorineural hearing impairment with unclear etiology and unsatisfying treatment effects. Vestibular dysfunction has been considered as a poor indicator in the clinical manifestations and prognosis of ISSNHL, which occurred in approximately 28-57% cases. Glucocorticoids, administered through oral or intratympanic way, are currently regularly and standardly applied for ISSNHL to improve the hearing outcome. However, the vestibular prognosis of ISSNHL after routine treatments remains seldom explored. This study aims to compare the effectiveness of oral and intratympanic glucocorticoids in ISSNHL with vestibular dysfunction in terms of the pattern and trajectory of possible process of vestibular function recovery. METHODS/DESIGN: A randomized, outcome-assessor- and analyst-blinded, controlled, clinical trial (RCT) will be carried out. Seventy-two patients with ISSNHL complaining of vestibular dysfunction appearing as vertigo or imbalance will be recruited and randomized into either oral or intratympanic glucocorticoid therapy group with a 1:1 allocation ratio. The primary outcomes will be vestibular function outcomes assessed by sensory organization test, caloric test, video head impulse test, cervical vestibular evoked myogenic potential, and ocular vestibular evoked myogenic potential; the secondary outcomes include self-reported vestibular dysfunction symptoms; dizziness-related handicap, visual analogue scale for vertigo and tinnitus; and pure tone audiometry. Assessments of primary outcomes will be performed at baseline and at 4 and 8 weeks post-randomization, while assessments of secondary outcomes will be performed at baseline and 1, 2, 4, and 8 weeks post-randomization. DISCUSSION: Previous intervention studies of ISSNHL included only hearing outcomes, with little attention paid on the prognosis of vestibular dysfunction. This trial will be the first RCT study focusing on the progress and prognosis of vestibular dysfunction in ISSNHL. The efficacy of two commonly used therapies of glucocorticoids will be compared in both auditory and vestibular function fields, rather than in the hearing outcome alone. TRIAL REGISTRATION: ClinicalTrials.gov NCT03974867 . Registered on 23 July 2019.
引用
- Hao W, Zhao L, Yu H, et al. Vestibular prognosis in idiopathic sudden sensorineural hearing loss with vestibular dysfunction treated with oral or intratympanic glucocorticoids: a protocol for randomized controlled trial. Trials. 2020. PMID: 32698830. doi:10.1186/s13063-020-04579-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。